Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EGFR-mutated lung cancer
Biotech
AstraZeneca, Daiichi share data behind Dato-DXd do-over
The partners showed subgroup overall survival data that exceeded the result seen in the broader population, providing evidence to support the pivot.
Nick Paul Taylor
Dec 6, 2024 5:21am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
AstraZeneca plants an EGFR tree with Pinetree deal worth $45M
Jul 23, 2024 2:16pm
Blueprint drops lung cancer programs after seeing early data
Jan 9, 2024 9:22am
AstraZeneca picks up a friend for Tagrisso in $40M upfront deal
Jan 2, 2024 10:52am
ASCO: Affimed pivots to cancer combo as monotherapy falls short
Jun 5, 2023 6:27am
